The new Scientific Advisory Board (SAB) has been set up, comprising eleven of the world's leading expert oncologists.
The new Scientific Advisory Board (SAB) has been officially established at the European Institute of Oncology, composed of eleven of the world's leading oncologists including Anton Berns from the Netherlands Cancer Institute (NL), Peter Boyle from the International Prevention Research Institute (FR), Otis Brawley from the American Cancer Society (USA), Carlo Croce from the Ohio State University - Comprehensive Cancer Center (USA), Giulio Draetta of the University of Texas - MD Anderson Cancer Center (USA), Silvia Franceschi of the Oncological Reference Center (CRO) of Aviano, Dieter Hoelzer of ONKOLOGIKUM Frankfurt (D), Robert Miller of the Mayo Clinic (USA), Ulrik Ringborg of the Cancer Center Karolinska (SV), Alphonse Taghian of Massachusetts General Hospital (USA) and Andrew von Eschenbach of the Samaritan Health Initiatives (USA). The task of this exceptional team is to analyze the Institute's clinical and research activities, to indicate new avenues for research, to promote exchanges and networking at national and international levels. The names of the new Board - said Professor Roberto Orecchia (pictured), IEO Scientific Director and President of SAB - confirm the prestigious position and absolute scientific importance of our Institute. The national and international oncology world looks to us as a model of experimentation of scientific innovation and of good clinical practice in oncology. Internationality is a fundamental aspect of the IEO and this has been our commitment since the beginning. To this end we have solid relationships with the most renowned international comprehensive cancer institutes and our new SAB guarantee further development. The first board brainstorming meeting, concludes Orecchia, confirmed that the strategic research choices of IEO, such as minimally invasive therapy, cell therapies and proton therapy, currently represent the best prospects in the fight against cancer. The board therefore supports our vision of IEO as " a major Institute for Precision Medicine in the future ".